Wan X - Search Results

1

A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer.

Shi W, Huang X, Wang Y, Wan X, He J, Xu Y, Zhang W, Chen R, Xu L, Zha X, Wang J. Shi W, et al. Among authors: wan x. Front Endocrinol (Lausanne). 2022 Nov 25;13:1042394. doi: 10.3389/fendo.2022.1042394. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506067 Free PMC article.

2

Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.

Zhang W, Xu Y, Shi X, Huang X, Chen R, Xu H, Shi W, Wan X, Wang Y, He J, Li C, Wang J, Zha X. Zhang W, et al. Among authors: wan x. Nanomedicine (Lond). 2022 Apr;17(10):683-694. doi: 10.2217/nnm-2022-0025. Epub 2022 Apr 8. Nanomedicine (Lond). 2022. PMID: 35393861

3

A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).

Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J. Huang X, et al. Among authors: wan x. Br J Clin Pharmacol. 2023 Jan;89(1):372-379. doi: 10.1111/bcp.15507. Epub 2022 Sep 7. Br J Clin Pharmacol. 2023. PMID: 36001055 Free article. Clinical Trial.

4

Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis.

Xu Y, Zhang W, He J, Wang Y, Chen R, Shi W, Wan X, Shi X, Huang X, Wang J, Zha X. Xu Y, et al. Among authors: wan x. Breast. 2022 Dec;66:8-14. doi: 10.1016/j.breast.2022.08.011. Epub 2022 Sep 2. Breast. 2022. PMID: 36084385 Free PMC article. Clinical Trial.

5

Corrigendum: A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer.

Shi W, Huang X, Wang Y, Wan X, He J, Xu Y, Zhang W, Chen R, Xu L, Zha X, Wang J. Shi W, et al. Among authors: wan x. Front Endocrinol (Lausanne). 2022 Dec 19;13:1109390. doi: 10.3389/fendo.2022.1109390. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36601017 Free PMC article.

6

Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer.

Shi W, Wan X, He J, Wang Y, Zhang W, Xu Y, Huang X, Chen R, Xu L, Zha X, Wang J. Shi W, et al. Among authors: wan x. J Investig Med. 2023 Apr;71(4):384-393. doi: 10.1177/10815589231151232. Epub 2023 Jan 19. J Investig Med. 2023. PMID: 36655808

7

Prognostic analysis of three forms of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment.

Zhang W, Xu Y, Wang Y, He J, Chen R, Wan X, Shi W, Huang X, Shi X, Wang J, Zha X. Zhang W, et al. Among authors: wan x. Cancer Med. 2023 Apr;12(8):9363-9372. doi: 10.1002/cam4.5693. Epub 2023 Feb 16. Cancer Med. 2023. PMID: 36794698 Free PMC article.

8

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response.

Xu Y, Zhang W, Wang S, Xu L, Xu H, Chen R, Shi X, Huang X, Wang Y, He J, Shi W, Wan X, Wang J, Zha X. Xu Y, et al. Among authors: wan x. Front Oncol. 2023 Feb 6;13:910869. doi: 10.3389/fonc.2023.910869. eCollection 2023. Front Oncol. 2023. PMID: 36814820 Free PMC article.

9

Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.

Shi W, Wan X, Wang Y, He J, Huang X, Xu Y, Zhang W, Chen R, Wang L, Zheng R, Ma L, Li X, Xu L, Zha X, Wang J. Shi W, et al. Among authors: wan x. Nanomedicine. 2023 Apr;49:102666. doi: 10.1016/j.nano.2023.102666. Epub 2023 Mar 6. Nanomedicine. 2023. PMID: 36889422

10

Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.

Zhang W, Wang Y, He J, Xu Y, Chen R, Wan X, Shi W, Huang X, Xu L, Wang J, Zha X. Zhang W, et al. Among authors: wan x. Nanomedicine. 2023 Nov;54:102707. doi: 10.1016/j.nano.2023.102707. Epub 2023 Sep 17. Nanomedicine. 2023. PMID: 37717927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,179 results

Search Page

Filters